Please wait a moment . . .

 

GLOBE Registry

NHS ethics-approved observational registry

Turning real-world weight experiences into evidence

GLOBE - Global Overweight & Obese Person Registry, is a global, ethics-approved registry for adults with a BMI over 25. We capture how overweight and obesity affect health, quality of life, work and costs – not just the number on the scales.

Adults with BMI > 25 Global, online participation Not a drug trial Real-world evidence (RWE)
Current status
Phase
Phase 1
Instrument development: patient & HCP surveys
Recruiting
Patients & HCPs
Adults with BMI > 25 and clinicians in weight management
Geography
Global
Online participation, English-speaking
Study type
Observational
No experimental treatments, no site visits

About the GLOBE Registry

What is GLOBE?

The Global Overweight & Obese Person Registry (GLOBE) is an international, observational research study for adults with a body mass index (BMI) over 25.

Its purpose is to understand how carrying extra weight affects people in the real world: their physical and mental health, day-to-day life, work, and personal finances – and how different weight-management approaches perform outside clinical trials.

GLOBE is not a diet programme and not a drug trial. It is not sponsored by any pharmaceutical company. We collect data, we do not prescribe treatments.

Why it matters
  • Most evidence used to make decisions about obesity care and funding comes from narrow populations in controlled trials.
  • Many people with BMI > 25 feel existing research does not reflect their lives or challenges.
  • Health services and payers need robust, patient-centred real-world evidence to design services and fund treatments fairly.
  • GLOBE aims to fill these gaps with data grounded in the lived experience of people with overweight and obesity.

For adults with BMI > 25

Who can take part?
  • 18 years or older.
  • Self-identify as having a BMI > 25 (overweight or obese).
  • Able to read and write English.
  • Have reliable internet access and an email address.
  • Willing to complete online questionnaires.
What you will do in Phase 1
  • Read an online Participant Information Sheet and provide e-consent if you agree.
  • Complete a short background questionnaire.
  • Complete two online surveys over roughly two months about your symptoms, quality of life and costs related to your weight.
  • Total time commitment for Phase 1 is expected to be under two hours.

In some countries, you may receive a small thank-you payment or voucher after you have completed both surveys, in line with local regulations.

What this study is NOT
  • It is not a diet or coaching programme.
  • It is not a trial of any specific medicine (e.g. Ozempic or Mounjaro).
  • You will not be asked to change your treatment as part of the study.
  • We will not tell your doctor how to treat you.

We will use anonymised data from many people like you to build a clearer picture of what changes when weight is managed – not only on the scales, but in your energy, mobility, mood, work and finances.

Register your interest as a participant

For healthcare professionals

Who we are looking for
  • Clinicians or allied health professionals who regularly manage adults with BMI > 25.
  • Working in primary care, endocrinology, bariatric surgery, obesity or weight-management services.
  • Able to complete online surveys in English.
Your role in Phase 1
  • Contribute to two structured online surveys.
  • Identify the symptoms, signs, comorbidities and service components you see in practice.
  • Prioritise which items must be captured in the final clinical and cost instruments.
  • Help ensure the registry reflects real-world practice rather than guideline ideals alone.
Honoraria & collaboration

Participants in the healthcare professional panel will receive an honorarium in line with fair-market-value rates for their specialty and country, in accordance with local regulations and institutional policies.

GLOBE is designed as a flexible platform for future research and service evaluation in overweight and obesity. We welcome collaboration with clinical centres, health systems, payers and academic partners.

Express interest as a healthcare professional

Study design & phases

Phase 1

Instrument development

Two-round online survey study with adults with BMI > 25 and healthcare professionals. The goal is to build disease-specific instruments capturing:

  • Symptoms and signs.
  • Quality-of-life impacts.
  • Healthcare and non-healthcare costs.
Phase 2

GLOBE Registry

Prospective, observational registry in which at least 100 adults with BMI > 25 complete a brief digital questionnaire monthly for at least 12 months, tracking:

  • Weight and weight-management approaches.
  • Comorbidities and symptoms.
  • Quality of life and functioning.
  • Resource use and personal costs.
Analysis & impact

Real-world evidence outputs

Data from GLOBE will be used to generate:

  • Descriptive and comparative analyses of real-world weight-management journeys.
  • Health economic models for payers and policymakers.
  • Evidence to inform guidelines, service design and funding decisions.

Ethics, data protection & wellbeing

Ethics approval

GLOBE has received a favourable opinion from an NHS Research Ethics Committee. The study is conducted in accordance with the Declaration of Helsinki and applicable data-protection regulations (including GDPR where relevant).

Data handling
  • Participants provide informed consent before any data are collected.
  • Data are stored securely on password-protected systems with restricted access.
  • Each participant is assigned a study ID; names and direct identifiers are kept separate.
  • Publications and presentations will only use anonymised, aggregated data.
Your choices & emotional safety
  • Participation is voluntary. You may withdraw at any time without giving a reason.
  • You may skip any question you do not wish to answer.
  • Some people may find questions about weight or quality of life upsetting. Support options and contact details are provided in the Participant Information Sheet.

GLOBE is an observational study only. It does not replace advice from your usual healthcare professionals. If you have concerns about your health, you should contact your doctor or local health services.

Frequently asked questions

Is this a trial of Ozempic, Mounjaro or other GLP-1 medicines?
No. GLOBE is not a drug trial and is not sponsored by any pharmaceutical company. We collect information on many different weight-management approaches, including but not limited to GLP-1 receptor agonists. Your treatment is decided by you and your clinician, not by the study team.
Will taking part change my medical care?
No. GLOBE is observational only. We do not prescribe medicines, recommend specific treatments or interfere with your usual care. For personal medical advice, you must speak to your own doctor.
Do I have to live in the UK to take part?
No. GLOBE is a global study. If you are an adult with BMI > 25, can read and write in English, and have internet access, you may be eligible regardless of your country of residence.
Will I be paid for taking part?
In some countries, a small thank-you payment or voucher may be offered to patient participants after completing required surveys, in line with local regulations. Healthcare professionals participating in Phase 1 receive an honorarium in line with fair-market-value rates for their role and country.
Can I withdraw from the study?
Yes. You can stop taking part at any time, without giving a reason and without affecting your medical care. Data already collected may still be used in anonymised form, as explained in the Participant Information Sheet.

Participant documents

The following documents provide detailed information about the study. Please ensure you have read the appropriate Participant Information Sheet in full before deciding whether to take part.

  • Participant Information Sheet – Patients (Phase 1)
    PDF | v1.x | For adults with BMI > 25 invited to the survey panel
    Download
  • Participant Information Sheet – Healthcare Professionals (Phase 1)
    PDF | v1.x | For clinicians invited to contribute to the awareness rounds
    Download
  • Participant Information Sheet – Registry (Phase 2)
    PDF | v1.x | For adults with BMI > 25 invited to join the registry
    Download
  • Consent Form – Patients (e-consent template)
    PDF | v1.x | For reference only – actual consent completed online
    Download
  • Consent Form – Healthcare Professionals (e-consent template)
    PDF | v1.x | For reference only – actual consent completed online
    Download

How to access the GLOBE study

Getting started

Participation in the GLOBE Registry takes place through the Medialis platform. You can access the study using a web browser on desktop or the Medialis mobile app.

  1. Contact us at info@medialis.co.uk.
  2. Open Medialis Insights App on your chosen device (desktop browser or mobile app).
  3. Create your account using the email address provided for the research. A verification code will be sent to your email.
  4. Sign in and enter your study access code to unlock the GLOBE study.
  5. Complete the questionnaires, starting with Consent and Demographics. Click into the next questionnaire tile to continue.

If you cannot find the verification email, please check your spam or junk folder.

Your study access
Study access code
6-digit code

This code will be sent after the validation of your participation via email.

**Emails are sent from these two official addresses: info@medialis.co.uk, research@medialis.co.uk. **If the study does not appear, please confirm that you registered using the same email address that was used to invite you to the research.

Contact & expressions of interest

Expressions of interest

If you are an adult with BMI > 25, a healthcare professional, or an organisation interested in collaborating with the GLOBE Registry, please contact the study team using the email address below.

This study cannot be used for medical emergencies. If you need urgent medical assistance, please contact your local health services immediately.

Email: INFO@MEDIALIS.CO.UK

Email: RESEARCH@MEDIALIS.CO.UK

Connect, follow and have a conversation with us

Medialis is a medical affairs consultancy servicing the pharmaceutical industry. Unlike some other agencies, we are proactive, not reactive or one-dimensional - if you need it, we can do it.

Medialis is a medical affairs consultancy servicing the pharmaceutical industry. Unlike some other agencies, we are proactive, not reactive or one-dimensional – if you need it, we can do it.